Vanguard

High-titer, Low-passage Parvovirus Vaccines

Seroconversion of puppies following vaccination with Vanguard^® Plus CPV

• Reduce the “window of susceptibility” that has been the major cause of CPV vaccination failure.
• The high-titer, low-passage vaccine virus in Vanguard^® Plus CPV is highly immunogenic and capable of stimulating active immunity in the presence of maternal antibodies.

In a 60-puppy study of (30) Vanguard^® Plus parvovirus vaccinates, all puppies seroconverted^† within 21 days of a third vaccination at 12 weeks of age.¹

† 4-fold increase in titer

1. Coyne MJ. Seroconversion of puppies to canine parvovirus and canine distemper virus: A comparison of two combination vaccines. J Am Anim Hosp Assoc 2000;36:137-142.

All brands are the property of Pfizer Inc., its affiliates and/or its licensors. Copyright © 2009 Pfizer Inc.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product label indications in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace consultation with your veterinarian. All decisions regarding animal health care must be made with a veterinarian, considering the unique characteristics of the patient.